,
The only targeted drug is now the only targeted medicine to treat patients with BP in the US
BP, which mainly affects elderly patients, is an chronic, weak and rare skin disease, which is characterized by acute itching, painful blisters and lesions, as well as makes the skin red. It is affecting around 27,000 adults in the country, whose disease is uncontrolled by systemic corticosteroids.
Dupixent is an injection administered under the skin (leather injection) on various injection sites.
The FDA approval was based on the pivatal adept phase 2/3 trial data compared to the placebo in medium-to-serious BP adults, which evaluated dupatta efficacy and safety in adults with medium to severe BP compared to Placebo. The results showed the exemption of the disease and the cut in the use of itching and oral corticosteroids compared to the placebo.
In the elderly population, more often the most commonly seen in patients on dupattas compared to placebo was arthralgia, conjunctivitis, blurred vision, herpes viral infections and keratitis.
George Yankopolos, the co-chairman of the board, the chairman at the Regoron and a leading inventor of the dupixent, and the dupixent said that the dupatta has shown the ability to improve the most challenging effects of the bulus pemphigoids, while some patients have helped in the use of continuous disease and decrease the use of oral corticosteroids.
Elisa Johnson, head of the global medical field, immunology and oncology development in Sanofi said, “Till now, treating bulus pemphigoids was very challenging for elderly patients, who were struggling with the weak effects of blisters and wounds, and potentially co-operation. The patients were conflicting patients. Permission to reduce.
In the US, dupattas are now approved to treat eight different diseases with underlying type 2 inflammation, including skin diseases, intestines and respiratory systems that affect different patients, from infants to elderly people.
For such health news, travel rttnews.com
The idea and opinion expressed here are the idea and opinion of the author and not necessarily Nasdac, Inc.
